ORKA-001 for Plaque Psoriasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test the long-term safety and effectiveness of ORKA-001 for individuals with moderate-to-severe plaque psoriasis. Participants will receive the treatment either once a year, twice a year, or not at all until certain conditions are met. The study is open to those who completed a previous trial with ORKA-001 without significant side effects. It is an excellent opportunity for individuals managing plaque psoriasis to explore continued treatment options. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important findings.
Is there any evidence suggesting that ORKA-001 is likely to be safe for humans?
Studies have shown that ORKA-001 is generally safe for people with moderate-to-severe plaque psoriasis. In a previous study, participants tolerated the treatment well, with no serious side effects reported. The number of minor side effects was similar to those in the placebo group (a substance with no active drug). These findings suggest that ORKA-001 has a clean safety profile, meaning it didn't cause significant health issues for participants in these studies. This treatment belongs to a drug class known for its safety and is being considered for long-term use.12345
Why are researchers excited about this trial's treatment for psoriasis?
Most treatments for plaque psoriasis, like biologics and topical steroids, require frequent administration and can have systemic side effects. ORKA-001 is unique because it offers a less frequent dosing schedule, with options for once or twice yearly administration. This could significantly improve convenience and adherence for patients. Additionally, it might work through a novel mechanism of action, potentially offering an alternative for those who do not respond well to existing therapies. Researchers are excited about ORKA-001 because it promises a more manageable treatment routine with the potential for effective symptom control.
What evidence suggests that ORKA-001 might be an effective treatment for plaque psoriasis?
Research has shown that ORKA-001 holds promise for treating moderate-to-severe plaque psoriasis. In one study, 63.5% of participants achieved completely clear skin by week 16, meaning nearly two out of three people showed no visible signs of psoriasis after using the treatment. The safety profile of ORKA-001 is similar to other treatments in its category, indicating it is generally well-tolerated. Participants in this trial will receive ORKA-001 either once yearly or twice yearly, while some will receive no drug until meeting a specific response criterion. These findings suggest that ORKA-001 could be an effective option for those dealing with plaque psoriasis.12356
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Open-label Treatment
Participants receive ORKA-001 treatment either once yearly or twice yearly as per protocol
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ORKA-001
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Active Control
Participants will receive ORKA-001 every 6 months per OLE protocol.
Participants will receive ORKA-001 once a year per OLE protocol.
Participants will receive no drug until protocol defined PASI response criterion is met.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oruka Therapeutics, Inc.
Lead Sponsor
Citations
1.
ir.orukatx.com
ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-announces-positive-week-16-data-orka-001/Release Details - Investor Relations | Oruka Therapeutics, Inc.
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16. Favorable safety profile consistent with the IL-23p19 class. Updated Phase 1 PK/PD data continue to ...
Oruka reports positive data from Phase IIa trial for plaque ...
At week 16, 40 of 63 participants receiving ORKA-001 achieved PASI 100, corresponding to complete skin clearance. Salong Debbarma April 28, 2026.
3.
fiercebiotech.com
fiercebiotech.com/biotech/orukas-psoriasis-data-hailed-outright-win-over-skyrizi-spurring-big-blockbuster-forecastsOruka's psoriasis data hailed as 'outright win over Skyrizi'
Oruka Therapeutics' long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading Jefferies ...
Study Details | NCT07090330 | ORKA-001 Versus Placebo ...
This is a proof-of-concept study evaluating ORKA-001 in patients with moderate-to-severe psoriasis with study drug administration divided into an Induction ...
Phase 1 Clinical Data of ORKA-001, a Novel Half-Life ...
ORKA-001 was well-tolerated across all dose levels, with a favorable safety profile consistent with the IL-23p19 inhibitor class. These ...
Phase 1 Clinical Data of ORKA-001, a Novel Half-Life ...
ORKA-001 was well-tolerated across all dose levels, with a favorable safety profile consistent with the IL-23p19 inhibitor class. These ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.